383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma

Background

The body mass index (BMI) before therapy shows a variety of progression free survival (PFS), it was said in the BMI study <18.5 kg/m2, had a worse progression free survival, compared to BMI 18.5-24.9 kg/m and BMI >24.9 kg/m2. The neutrophil lymphocyte ratio before therapy showed a variety of progression free survival (PFS). It was said that NLR ≥ 3 patients study have a better progression free survival compared to those < 3, but these results are still contradictory. The aim of this study was to determine body mass index and neutrophil to lymphocyte ratio before therapy to predict 3-year progression free survival in patients with locally advanced nasopharyngeal carcinom.

Methods

Patients with locally advanced nasopharyngeal carcinoma (N=289) from 2015 until 2017 who underwent chemoradiation with and without adjuvant or neoadjuvant chemotherapy were enrolled. Body mass index before therapy was classified as <18.5 (underweight), 18.5-24.9 (normal), and >24.9 (overweight or obese) and the neutrophil to lymphocyte ratio before therapy was categorized as ≥3 and <3, using the Cox proportional hazard and Kaplan-Meier models.

Results

Body mass index 18.5-24.9 and 24.9 on Cox regression has a better 3-year PFS with adjusted hazard ratio (HR = 0.219; CI = 1.43-1.59; p = 0.025 and HR = 0.136 ; CI = 1.51-1.76; p = 0.025 ), BMI <18.5 indicates a lower 3-year PFS (HR=1.644; CI=1.28-1.56; P=0.001). While NLR ≥3 before therapy had a better 3-year PFS (HR=0.152; CI 1.37-1.53, p=0.001) than NLR <3 (HR=1.603; CI 1.52-1.69, p=0.013.

Conclusions

Patients with BMI<18.5 before therapy had a lower 3-year PFS, and BMI>24.9 had a 3-year higher PFS than the normal weight group and NLR ≥3 had a higher PFS than under 3. This study provides a good understanding better between BMI and PFS and NLR and PFS, but further research is needed to confirm the result in different populations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.